Catalent Pharma Solutions today announced that it has signed the CEO Action for Diversity and Inclusion pledge, the largest CEO-driven business commitment for advancing diversity and inclusion in the workplace.
SOMERSET, N.J. – March 21, 2019 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has signed the CEO Action for Diversity and Inclusion pledge, the largest CEO-driven business commitment for advancing diversity and inclusion in the workplace.
This pledge recognizes that diversity and inclusion is not just a competitive issue, but a societal one that CEOs can play a critical role in addressing.
John Chiminski, Catalent’s Chair and Chief Executive Officer commented, “Research shows that diversity increases creativity and innovation, promotes higher quality decisions, and enhances economic growth.” He added, “We are fully committed to implementing programs which will see the introduction of additional employee resource groups to support veterans, members of the LGBTQ+ community, Latinos, Pan-Asians, women, young professionals and black employees.”
Mr. Chiminski joins more than 550 CEOs of the world’s leading companies and business organizations, with the aim of advancing diversity and inclusion. The CEO Action Pledge outlines a specific set of actions that participating organizations will take to cultivate a trusting environment where all ideas are welcomed, and employees feel comfortable and empowered to discuss diversity and inclusion.
For more information on the CEO Action for Diversity and Inclusion program visit ceoaction.com.
+44 (0)7580 041073
+44 (0)161 728 5880
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.